TerminatedPhase 3

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

United States65 participantsStarted 2007-04

Plain-language summary

Approximately 65 patients will be entered into this study taking place in North America. The aim of this study is to evaluate the safety, efficacy and absorption of an investigational drug in patients with C. difficile-associated diarrhea (CDAD). All study related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is 6 weeks.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The presence of CDAD at the time of enrollment * Negative serum pregnancy test (HCG) for women of childbearing potential. Exclusion Criteria: * Any contraindication to oral / enteral therapy including fulminant C. difficile disease. * Any acutely life-threatening medical conditions. * Acute or chronic diarrhea of other cause.

What they're measuring

Clinical Success

Safety

Trial details

NCT IDNCT00466635

SponsorGenzyme, a Sanofi Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Enterocolitis, Pseudomembranous trials